6
References
1. Uchiyama, S., Liquid formulation for antibody drugs. Biochim Biophys Acta, 2014. 1844(11): p. 2041-
2052.
2. Brader, M.L., et al., Examination of thermal unfolding and aggregation profiles of a series of
developable therapeutic monoclonal antibodies. Mol Pharm, 2015. 12(4): p. 1005-17.
3. Rouet, R., D. Lowe, and D. Christ, Stability engineering of the human antibody repertoire. FEBS Lett,
2014. 588(2): p. 269-77.
4. Tiller, K.E. and P.M. Tessier, Advances in Antibody Design. Annu Rev Biomed Eng, 2015.
5. Cerasoli, E., et al., Temperature denaturation and aggregation of a multi-domain protein (IgG1)
investigated with an array of complementary biophysical methods. Anal Bioanal Chem, 2014.
406(26): p. 6577-86.
6. Menzen, T. and W. Friess, Temperature-ramped studies on the aggregation, unfolding, and
interaction of a therapeutic monoclonal antibody. J Pharm Sci, 2014. 103(2): p. 445-55.
7. Menzen, T. and W. Friess, High-throughput melting-temperature analysis of a monoclonal antibody
by differential scanning fluorimetry in the presence of surfactants. J Pharm Sci, 2013. 102(2): p. 415-
28.
8. Garidel, P.K., A.R.; Blech, M. , Orthogonal spectroscopic techniques for the early developability
assessment of therapeutic protein candidates. Spectroscopy Europe, 2014. 26(4): p. 9-13.
9. Garidel, P., Right Angle Light Scattering protein thermostability screening: for research and
development. Spectroscopy Europe, 2012. 24(1): p. 13-18.
